A Cold War-era initiative designed to boost domestic vaccine manufacturing is resurfacing as a potential tool in the fight against counterfeit and substandard medicines. The program, originally created to strengthen public health infrastructure, may now offer a framework for improving oversight and supply chain integrity in pharmaceuticals. With concerns growing over the global spread of falsified drugs, officials are exploring how legacy policies could be adapted to modern challenges. The revival of such strategies could mark a shift in how governments and health organizations approach drug safety and verification.
How a Reagan-era program to promote vaccine production could play a role in Kennedy’s crusade against the medications
